Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

REEF-1 Study Group

医学部・消化器内科学・第１

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

フィンガープリント

「Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

並べ替え順

重み付け
アルファベット順

Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

フィンガープリント

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases